Gastric mucosal atrophy (GMA) (GMA)

Gastric mucosal atrophy is a histopathological condition and disease state rather than a specific therapeutic target molecule such as a receptor or enzyme [1, 9]. It is characterized by the chronic inflammation of the stomach lining, leading to the progressive loss of specialized glandular cells, including parietal and chief cells [1, 6]. This loss often results in the replacement of the normal gastric mucosa with intestinal-type epithelium (intestinal metaplasia) or fibrous tissue [1, 9]. The condition is primarily driven by long-term Helicobacter pylori infection or autoimmune destruction of parietal cells, the latter of which is associated with pernicious anemia [6, 9]. Gastric mucosal atrophy is a well-recognized precursor in the Correa cascade of gastric carcinogenesis, significantly elevating the risk for gastric adenocarcinoma [9, 10]. Clinical management typically involves the eradication of H. pylori using antibiotics and acid suppressants, monitoring for nutritional deficiencies like Vitamin B12 and iron, and regular endoscopic surveillance to detect early neoplastic changes [12, 15]. While not a single molecular target, its progression is associated with various signaling pathways, including NF-κB and Wnt/β-catenin, which are under investigation for therapeutic intervention [3].

Other names

Atrophic gastritisChronic atrophic gastritisGastric atrophyType A gastritisType B gastritisEnvironmental metaplastic atrophic gastritisAutoimmune metaplastic atrophic gastritis

Treatment strategies focus on the eradication of Helicobacter pylori through combination antibiotic therapy and acid suppression, or the replacement of essential micronutrients in autoimmune-mediated cases.